Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12

GlobeNewswire August 24, 2017

AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis

GlobeNewswire August 23, 2017

AzurRx BioPharma Announces Closing of $5.0 Million Private Financing

GlobeNewswire June 8, 2017

AzurRx BioPharma to Present at the 2017 LD Micro Invitational Conference (June 6) and the 2017 Marcum MicroCap Conference (June 15)

GlobeNewswire June 5, 2017

AzurRx Provides Update on MS1819 Phase II Trial

GlobeNewswire April 11, 2017

AzurRx Announces Addition of Charles J Casamento to the Board of Directors

GlobeNewswire March 8, 2017

AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference

GlobeNewswire December 28, 2016

Biotech Stocks Head Into 2017 With Clinical Developments That Could Lead to Growth and Added Value

PR Newswire December 21, 2016

AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency

GlobeNewswire December 21, 2016

New Collaborations and Licensing Activities for Biotech/Pharma Industries Pick Up Pace Heading into 2017

PR Newswire December 6, 2016

AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology

GlobeNewswire December 6, 2016

Biotech Sector Growth Expected Upon Diminishing Concerns Over Drug Pricing

PR Newswire December 1, 2016

AzurRx CEO Provides Shareholders With a "State of the Union" Communication

GlobeNewswire December 1, 2016

AzurRx BioPharma to Present at the 9th Annual LD Micro Main Event

Accesswire November 30, 2016

AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients

GlobeNewswire November 17, 2016

AzurRx BioPharma Inc. (Nasdaq: AZRX) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire October 19, 2016

AzurRx BioPharma Announces Pricing of Initial Public Offering

Business Wire October 12, 2016